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Abstract
Introduction Asymmetrical dimethyl arginine (ADMA) is an
endogenous non-selective inhibitor of nitric oxide synthase that
may influence the severity of organ failure and the occurrence of
shock secondary to an infectious insult. Levels may be
genetically determined by a promoter polymorphism in a
regulatory gene encoding dimethylarginine
dimethylaminohydrolase II (DDAH II), which functions by
metabolising ADMA to citrulline. The aim of this study was to
examine the association between ADMA levels and the severity
of organ failure and shock in severe sepsis and also to assess
the influence of a promoter polymorphism in DDAH II on ADMA
levels.
Methods A prospective observational study was designed, and
47 intensive care unit (ICU) patients with severe sepsis and 10
healthy controls were enrolled. Serum ADMA and IL-6 were
assayed on admission to the ICU and seven days later. Allelic
variation for a polymorphism at position -449 in the DDAH II
gene was assessed in each patient. Clinical and demographic
details were also collected.
Results On day 1 more ADMA was detectable in the ICU group
than in the control group (p  = 0.005). Levels subsequently
increased during the first week in ICU (p = 0.001). ADMA levels
were associated with vasopressor requirements on day one (p
= 0.001). ADMA levels and Sequential Organ Failure
Assessment scores were directly associated on day one (p =
0.0001) and day seven (p = 0.002). The degree of acidaemia
and lactaemia was directly correlated with ADMA levels at both
time points (p  < 0.01). On day seven, IL-6 was directly
correlated with ADMA levels (p = 0.006). The variant allele with
G at position -449 in the DDAH II gene was associated with
increased ADMA concentrations at both time points (p < 0.05).
Conclusion Severity of organ failure, inflammation and
presence of early shock in severe sepsis are associated with
increased ADMA levels. ADMA concentrations may be
influenced by a polymorphism in the DDAH II gene.
Introduction
Overwhelming infection with resultant multiple organ failure,
which has been termed the 'sepsis syndrome' [1], is a devas-
tating illness, and a common intensive care unit (ICU) admis-
sion diagnosis, with an incidence of 3 per 1,000 population
per annum [2]. The sepsis syndrome has been characterised
as a dysregulation of inflammation in response to infection,
with life-threatening organ failure attributable to a combination
of excessive inflammation, disseminated coagulopathy and
disruption of the integrity of microvascular endothelium [3].
ADMA = asymmetrical dimethyl arginine; DDAH = dimethylarginine dimethylaminohydrolase; ELISA = enzyme-linked immunosorbent assay; eNOS = 
endothelial NO synthase; iNOS = inducible NO synthase; ICU = intensive care unit; IL = interleukin; NO = nitric oxide; NOS = nitric oxide synthase; 
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Endothelium-derived nitric oxide (NO) is a potent vasodilator
that antagonises the effects of endogenous vasopressors [4].
NO is produced from L-arginine by an enzyme, nitric oxide syn-
thase (NOS), which exists in constitutive, inducible, endothe-
lial and neuronal isoforms. The endothelial isoform (eNOS)
regulates vascular tone and interactions between leukocytes
and endothelium [5]. Consequently, NO has been implicated
in the pathogenesis of the hypotension and organ failure attrib-
utable to severe sepsis [6]. However, although non-selective
pharmacological inhibition of NOS briefly attenuates the
haemodynamic anomalies seen in these patients with severe
sepsis, the overall effect of such inhibition is to increase mor-
tality [7].
This conundrum may be explained in part either by selective
inhibition of the various isoforms of NOS or by an ancillary non-
vascular function of NOS. Specifically, inhibition of the consti-
tutively expressed isoform of NOS, which is essential to main-
tain organ perfusion, may be detrimental [8]. However, and of
considerably greater importance in the context of sepsis, NO
has an ancillary yet critical protective function, possessing
potent antimicrobial properties, antagonism of which may
account for the excess mortality observed with NOS inhibition
in patients with sepsis [9].
Asymmetrical dimethyl arginine (ADMA) is a naturally occur-
ring non-selective inhibitor of NOS, derived from protein
catabolism, and is metabolised to citrulline by dimethylarginine
dimethylaminohydrolase (DDAH) [10]. The co-localisation of
DDAH and NOS at several sites supports the hypothesis that
DDAH may regulate NOS activity by controlling the metabo-
lism of ADMA [10]. DDAH exists as two distinct isoforms, with
DDAH I present in tissues expressing neuronal NOS, whereas
DDAH II has an expression pattern similar to that of eNOS
[11], thus making DDAH II characteristic of vascular tissue
such as the heart and endothelium. Variation in DDAH II
expression or activity might therefore be an important mecha-
nism in the haemodynamic alterations and end-organ damage
observed in sepsis. Notably, DDAH displays decreased activ-
ity when operating in an inflammatory milieu [12]. Depletion of
NO by ADMA has biological significance, because elevated
ADMA levels are seen in patients with vascular disease,
hepatic failure and renal failure, and are linked with greater
severity of organ failure in ICU patients with sepsis [5,13]. Fur-
thermore, it has recently been postulated that the beneficial
effects of the administration of exogenous insulin may be asso-
ciated with fluctuations in ADMA levels in patients with sepsis
[13]. However, variation in ADMA levels may also have a
genetic basis. Gene polymorphism, observed in the promoter
region of the DDAH II gene, may have functional significance
[14] but has not previously been studied in a human popula-
tion with sepsis. However, an association between gene poly-
morphism in the promoter region of the DDAH II gene and
systemic arterial vasodilation after cardiac surgery with cardi-
opulmonary bypass suggests a link between pathological
vasodilation, such as that occurging with severe sepsis, and
ADMA metabolism [15].
We undertook a study to assess the relationship between
ADMA levels and organ failure in ICU patients with severe sep-
sis and also to assess the possible functionality of a polymor-
phism in the DDAH II promoter, designated DDAH II -449
(single-nucleotide polymorphism (SNP) ID rs805305).
Materials and methods
This study was conducted in the ICU of St James's Hospital,
Dublin, Ireland, and was approved by the local research ethics
committee. Informed written consent was obtained from each
patient or a first-degree relative. A total of 47 consecutive
patients with severe sepsis or septic shock, as defined by the
American College of Chest Physicians/Society of Critical
Care Medicine Consensus Conference [1] were enrolled. Ten
healthy staff members served as a control group.
Severity of illness was characterised with the Sequential
Organ Failure Assessment (SOFA) scoring system [16] and
the Simplified Acute Physiology Score (SAPS2) [17] on
admission to ICU, and with the SOFA score again on day
seven. Individual clinical and laboratory variables relating to
inflammation were collected on days one and seven of ICU
stay. The recorded variables represented the most significant
derangements from normal values recorded over each 24-
hour period. The requirement for vasoactive or vasopressor
medications to maintain a mean arterial pressure greater than
60 mmHg was recorded. These medications consisted of
either adrenaline or noradrenaline infusions. Death in ICU or
survival to ICU discharge was recorded.
Blood sampling was performed within the first 24 hours of ICU
admission and again seven days later through an indwelling
central venous line. Serum was obtained from whole blood
clotted for 30 minutes at room temperature and spun at 2,500
rev./minute for 10 minutes.
ADMA was measured with a microtitre plate assay (DLD Diag-
nostika Ltd, Hamburg, Germany) as described previously [18].
Serum IL-6 concentrations were measured by ELISA (R&D
Systems, Minneapolis, MN, USA) in accordance with the man-
ufacturer's instructions. The lower limit of detection for IL-6
was 9.4 pg/ml. All samples were tested in duplicate.
Genomic DNA was extracted from whole blood with a com-
mercially available DNA isolation kit (QIAmp DNA blood Midi
kit, Qiagen GmBH, Crawley, West Sussex, UK). Allelic varia-
tion for the polymorphism was assayed using Amplifluor tech-
nology by Kbiosciences (Hoddesdon, Herts., UK). Primer
sequences are listed in Table 1.Available online http://ccforum.com/content/10/5/R139
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Statistical analysis was performed with the JMP software
package (SAS, Cary, NC, USA). Between-group comparisons
for continuous variables were analysed by Wilcoxon rank sum
test, Wilcoxon sign rank test and Kruskal-Wallis test where
appropriate. Spearman's rank correlation coefficient was used
to analyse the relationship between continuous variables. For
all comparisons, p < 0.05 was considered significant.
Results
Consent was gained for 47 ICU patients and from 10 healthy
controls; they were recruited into the study. Blood samples
were available for analysis from 40 patients on day 1 and from
35 patients on day 7; 28 patients had blood samples available
for analysis at both time points. Fourteen (30%) patients died
before discharge from ICU. Demographic data, clinical details
and levels of inflammatory markers for patients are detailed in
Tables 2 to 4.
Day one comparisons
On day one, 31 patients (66%) required infusion of a vasoac-
tive compound to maintain adequate arterial pressure. ADMA
levels (p = 0.001), lactate levels (p = 0.018) and organ failure
scores (p < 0.003) were higher in this group requiring vasoac-
tive infusions (Table 3). Patients in this group on day one were
also more likely to be non-survivors (p = 0.01; Table 3).
Plasma lactate levels were directly correlated with ADMA lev-
els on day 1 (r2 = 0.28, n = 40, p = 0.0003). In addition, SOFA
Table 1
Locus Primer




Demographics and asymmetrical dimethyl arginine (ADMA) levels by group
Parameter Survivors Non-survivors p
Total patients 33 (70) 14 (30)
Male sex 17 (52) 9 (64) ns
SOFA score, day 1 7 (4–10) 9 (8.75–12.5) 0.02
SOFA score, day 7 4 (2.75–7.25) 10.5 (8.5–11.75) 0.006
SAPS2 score 39 (30.5–51.5) 47.5 (39.5–60.75) ns
Lactate, day 1 2.1 (1.5–5) 3.6 (2.25–5.75) ns
Lactate, day 7 1.5 (1–1.9) 2 (1.1–4) ns
Vasoactive agents, day 1 18 (55) 13 (93) 0.01
Vasoactive agents, day 7 5 (15) 5 (63) 0.005
ADMA, day 1 0.88 (0.52–1.09) 0.91 (0.64–1.23) ns
ADMA, day 7 1.05 (0.66–1.21) 1.24 (0.77–1.53) ns
pH, day 1 7.31 (7.26–7.38) 7.33 (7.27–7.37) ns
pH, day 7 7.44 (7.40–7.45) 7.32 (7.24–7.40) 0.002
WCC, day 1 18 (10.7–23) 9.1 (2.3–17.8) ns
WCC, day 7 11.6 (8.6–17.4) 13.9 (8.5–19.3) ns
Base excess, day 1 -2.9 (-6.45 to 1.75) -4.1 (-9.3 to 1.75) ns
Base excess, day 7 2.9 (1.1–5.6) 0.1 (-3 to 1.33) 0.009
IL-6, day 1 277 (107–499) 782 (566–1,060) 0.001
IL-6, day 7 22 (0–651) 130 (68–425) ns
All values are shown either as absolute counts with percentages in parenthesis or as medians with interquartile ranges in parenthesis. ADMA was 
measured in µmol/l, lactate in mmol/l, and IL-6 in pg/ml. SOFA, Sequential Organ Failure Assessment score; SAPS, simplified acute physiology 
score; ADMA, asymmetrical dimethyl arginine; WCC, white cell count; ns, not significant.Critical Care    Vol 10 No 5    O'Dwyer et al.
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score and ADMA levels were directly correlated on day 1 (r2 =
0.31, n = 40, p < 0.0001).
To elucidate whether the relationship between ADMA levels
and SOFA score was entirely attributable to cardiovascular
failure, a non-cardiac organ failure score was obtained by
excluding the cardiovascular component from the total SOFA
score. There was a positive correlation between this score and
ADMA levels on day 1 (r2 = 0.23, n = 40, p = 0.002).
ADMA levels on day 1 were not related to survival, nor were
the highest producers of ADMA (highest quartile) more likely
to have a higher mortality. However, SOFA scores and IL-6 lev-
els on day one did distinguish between survivors and non-sur-
vivors on day 1 (p = 0.02 and p = 0.001, respectively) (Table
2).
Day seven comparisons
On day seven, 10 patients (24%) required infusion with
vasoactive medication to maintain a normal blood pressure.
Although there was a trend towards increasing ADMA levels
in those patients requiring vasoactive infusions to maintain
blood pressure, this did not reach significance (p  = 0.07;
Table 4).
Plasma lactate levels were directly correlated with ADMA lev-
els on day 7 (r2 = 0.18, n = 31, p = 0.01). In addition, SOFA
score and ADMA levels were directly correlated on day 7 (r2 =
0.23, n = 35, p = 0.002). The non-cardiac organ failure score
was calculated as above from the day 7 SOFA score. This
score was positively correlated with ADMA levels on day 7 (r2
= 0.22, n = 35, p = 0.005).
ADMA levels on day 7 were not related to survival, nor were
the highest producers of ADMA (highest quartile) more likely
to have a higher mortality. However, increased SOFA scores,
acidosis and requirement for infusion of vasoactive
medications on day 7 were associated with increased risk of
death (Table 2).
ADMA levels by group
On the first day of critical illness, the ICU group had greater
ADMA levels than the control group (p = 0.005). ADMA levels
Table 3
Requirement for vasoactive infusions on day 1
Parameter Vasoactive infusions No vasoactive 
infusions
p
Total patients 31 (66) 16 (34)
Death 13 (42) 1 (6) 0.01
IL-6 354 (189–768) 293 (87–657) ns
pH 7.31 (7.26–7.35) 7.32 (7.29–7.40) ns
Lactate 3.5 (1.9–6.02) 1.8 (1.05–3.75) 0.018
Base excess -3.5 (-9 to 3.4) -2 (-4.95 to 0.55) ns
SOFA 9 (8–12) 4 (3.25–4.75) <0.0001
SAPS2 47 (38–63) 33.5 (21–41.75) 0.003
ADMA 0.96 (0.82–1.29) 0.54 (0.48–0.78) 0.001
WCC 14 (8–22) 17 (8–24) ns
MAP 65 (60–70) 79 (66–80) 0.001
Heart rate 110 (90–120) 103 (96–118) ns
CVP 13 (10–16) 11 (7–12) ns
Noradrenaline 13 (5–26) -
All values are shown either as absolute counts with percentages in 
parenthesis or as medians with interquartile ranges in parenthesis. IL-
6 was measured in pg/ml, asymmetrical dimethyl arginine (ADMA) in 
µmol/l, lactate in mmol/l, and mean arterial pressure (MAP) and 
central venous pressure (CVP) in mmHg. Noradrenaline dosage was 
measured in µg/minute. SOFA, Sequential Organ Failure 
Assessment score; SAPS, simplified acute physiology score; WCC, 
white cell count; ns, not significant.
Table 4






Total patients 10 (24) 31 (76)
Death 5 (50) 3 (10) 0.005
IL-6 299 (20–784) 23 (0–117) 0.037
pH 7.36 (7.23–7.41) 7.44 (7.40–7.45) 0.0006
Lactate 2.35 (1.48–3.73) 1.2 (1–1.8) 0.006
Base excess 0.05 (4.7–3.8) 2.9 (1.1–4.8) 0.04
SOFA 11 (10–15) 4 (2.3–5.8) <0.0001
ADMA 1.21 (0.88–1.57) 1 (0.66–1.18) ns
WCC 18.2 (13.3–22.2) 10 (8.2–13.8) 0.01
MAP 70 (69–76) 82 (80–90) 0.01
Heart rate 100 (85–111) 78 (70–90) 0.04
CVP 11 (10–12) 10 (9–14) ns
Noradrenaline 12 (4–21) -
All values are shown either as absolute counts with percentages in 
parenthesis or as medians with interquartile ranges in parenthesis. IL-
6 was measured in pg/ml, asymmetrical dimethyl arginine (ADMA) in 
µmol/l, lactate in mmol/l, and mean arterial pressure (MAP) and 
central venous pressure (CVP) in mmHg. Noradrenaline dosage was 
measured in µg/minute. SOFA, Sequential Organ Failure 
Assessment score; WCC, white cell count; ns, not significant.
Table 5
Asymmetrical dimethyl arginine (ADMA) levels by group
Parameter Control Day 1 ICUa Day 7 ICUb
ADMA 0.63 (0.57–0.71) 0.89 (0.57–1.09) 1.05 (0.71–1.32)
All values are in µmol/l and are presented as medians with 
interquartile ranges in parenthesis. ICU, intensive care unit. 
aComparison between day 1 ICU and control group by Wilcoxon 
rank sum test; p = 0.005. bComparison between day 1 ICU and day 
7 ICU by Wilcoxon signed rank test; p = 0.001.Available online http://ccforum.com/content/10/5/R139
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subsequently rose over the first week in the ICU group (p =
0.001; Table 5).
Correlation between ADMA levels and inflammatory 
markers
Various inflammatory markers were correlated with ADMA lev-
els on univariate analysis on both day 1 and day 7 (Table 6).
Whereas pH, base excess and lactate levels were correlated
with ADMA on both day 1 and day 7, IL-6 levels were corre-
lated with ADMA only on day 7, and the white cell count was
not correlated with ADMA at either time point (Table 6).
Correlation between severity of organ failure and ADMA 
and IL-6 levels
Multivariate analysis of the relationship between the SOFA
scores and the biological markers ADMA and IL-6 revealed
that on day 1 both ADMA (p = 0.002) and IL-6 (p = 0.009)
were independently related to SOFA scores, whereas on day
7 only ADMA (p = 0.002) was independently related to the
SOFA score (Table 7).
Allelic variations
The distribution of DDAH II alleles conformed to a Hardy-
Weinberg equilibrium. There was no association between any
clinical outcome measure and carriage of specific DDAH II
alleles. Twenty-four patients (45%) were GG homozygotes, 5
(11%) were CC homozygotes and 19 (43%) were heterozy-
gotes at position -449 in the DDAH II promoter. There was a
trend towards increasing amounts of ADMA between different
DDAH II genotypes. ADMA was most abundant in the GG
homozygotes, least abundant in the CC homozygotes and
detectable at intermediate levels in the heterozygotes. This
trend was present at both time points, although it failed to
reach significance on either day 1 (p = 0.069) or on day 7 (p
= 0.32). However, carriage of the G allele at position -449 was
associated with increased ADMA production on both day 1 (p
= 0.03) and day 7 (p = 0.042) (Table 8).
Discussion
There are limited data on the role of ADMA and DDAH II in sys-
temic inflammation, with two studies of critically ill patients
observing a relationship between the highest producers of
ADMA and fatal outcome [5,13]. Although our study may not
have been adequately powered to detect outcome variations,
we have demonstrated both an increase in ADMA levels in crit-
ically ill patients in comparison with healthy controls and
described an association between increasing ADMA levels,
the occurrence of septic shock and greater severity of organ
failure.
Given the ubiquitous involvement of NO in vascular regulation
and leukocyte function, the consequences of excess ADMA in
inflammatory and septic states are likely to be manifold. Raised
ADMA levels may lead to pathogenic changes in the microvas-
culature by inhibiting constitutively expressed NOS [8]. The
consequent loss of basal NO production may lead to impaired
blood flow with platelet aggregation, causing endothelial dam-
age, interstitial oedema and resultant organ failure [19].
However, ADMA mediated inhibition of inducible NOS (iNOS)
in patients with sepsis may interfere with macrophage bacteri-
cidal properties, because NO is an essential component in the
phagocytic response to bacterial infection. Interferon-γ,
released in response to an infective insult, acts on macro-
phages to increase the expression of iNOS [9]. This activates
the cells to a heightened microbicidal state, mediated by NO
and adducts of the nitrogenous products of nitric oxide syn-
thases. As a consequence mice with a non-functional iNOS
gene are susceptible to infection [20]. Furthermore, in clinical
Table 6
Correlation matrix of asymmetrical dimethyl arginine (ADMA) 
and inflammatory markers
Parameter ADMA day 1 data ADMA day 7 data
pH 0.31 (0.0002) 0.32 (0.001)
Base excess 0.13 (0.02) 0.24 (0.005)
Lactate 0.29 (0.0003) 0.20 (0.01)
WCC ns ns
IL-6 ns 0.25 (0.006)
Values are r2 with p values in parenthesis. WCC, white cell count; ns, 
not significant.
Table 7
Multivariate linear regression between SOFA scores and 
ADMA and IL-6 levels
Parameter F ratio p
Day 1 (n = 36, r2 = 0.35)
ADMA 11 0.002
IL-6 7.8 0.009
Day 7 (n = 30, r2 = 0.32)
ADMA 12.02 0.002
IL-6 0.88 ns
SOFA, Sequential Organ Failure Assessment score; ADMA, 
asymmetrical dimethyl arginine; ns, not significant.
Table 8
Variation in asymmetrical dimethyl arginine (ADMA) levels with 
carriage of specific alleles at DDAH II -449
Day ADMA (µmol/l) p
GC/GG genotype CC genotype
1 0.91 (0.63–1.16) 0.51 (0.45–0.70) 0.03
7 1.06 (0.77–1.35) 0.835 (0.67–1.03) 0.04
Values are medians with interquartile ranges in parenthesis. Patients 
carrying variant allele with G at position -449 have either a GG or a 
GC genotype. DDAH, dimethylarginine dimethylaminohydrolase.Critical Care    Vol 10 No 5    O'Dwyer et al.
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trials of NOS inhibition in patients with sepsis, although NOS
inhibition ameliorates pathogenic vasodilation and lessens
vasopressor requirement, the overall effect is to compromise
survival [7]. This suggests, in the context of severe sepsis, that
NO-linked immune mechanisms are of greater importance
than NO-meditated vascular regulation.
We observed that elevated ADMA levels are correlated with
vasopressor support in early septic shock. Although this may
seem counterintuitive because previous evidence implicated
NO in the pathogenesis of the hypotension observed in septic
shock [21], it is plausible that inappropriately increased ADMA
levels may impair macrophage function by means of NOS inhi-
bition. The associated inflammatory response to an unresolved
infection may be partly responsible for the observed hypoten-
sion and organ failure operating through an alternative mecha-
nism. This persistent inflammatory response is reflected in the
linkages between IL-6, ADMA and the severity of organ failure
(Tables 6 and 7). The association with IL-6 is noteworthy
because this is a well-recognised marker of generalised
inflammation, consistently elevated in patients with sepsis
[22].
About 90% of ADMA is metabolised by the enzyme DDAH
[10]. It is possible that variation in ADMA levels in patients with
sepsis is reactive and represents an epiphenomenon. How-
ever, we observed that carriage of a G at position -449 in the
promoter region of the DDAH II gene is associated with
increased ADMA levels, which suggests that the DDAH II
gene with a G at this position is less active than that with a C.
The more active isoform results in lower ADMA levels, less
iNOS inhibition and consequently an appropriate bactericidal
phagocytic response. It is noteworthy that DDAH II maps to
6p21.3, a region of DNA that is particularly rich in genes
involved in immune and inflammatory responses. It has been
hypothesised that this location and wide expression in immune
cells make it a candidate as a disease susceptibility gene in
sepsis [10].
We have previously described an association between the
presence of a G at position -449 in the DDAH II gene and the
requirement for vasopressors after cardiopulmonary bypass
during cardiac surgery [15]. Although this is the opposite of
what we observed in septic patients, it is noteworthy that the
two insults are also quite different. The cardiopulmonary
bypass circuit invokes a sterile inflammatory response,
whereas the ICU patients with sepsis received an infective
inflammatory insult. Consequently, the role of ADMA in manip-
ulating NO levels may be context sensitive. NO may have piv-
otal beneficial bactericidal properties necessary for the
resolution of a septic insult while contributing to an undesira-
ble vasodilatory state in the setting of a sterile inflammatory
insult.
This potential genetic component to the fluctuations observed
in ADMA levels secondary to a septic insult may help to explain
some of the residual variability observed in a previous study
attempting to link exogenous insulin administration to ADMA
levels [13]. Thus, interindividual variability in ADMA production
is likely to be multifactorial, with contributions from genetic and
environmental factors.
Conclusion
We have confirmed the association between ADMA levels and
the extent of multiple organ failure in sepsis. We have also
demonstrated that ADMA levels are upregulated in response
to an infective insult and are also associated with hypotension
in this setting. We hypothesise that this may be due to ineffec-
tive bactericidal activity of macrophages and persistent inflam-
mation. Finally, we suggest that ADMA levels may be regulated
via a genetic component. We propose that a polymorphism at
position -449 in the DDAH II may be functional and has the
potential to be used as a marker for the susceptibility to and
severity of an inflammatory response secondary to an infective
insult. A larger study will be required to confirm these findings.
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Key messages
•  ADMA, an endogenous non-selective inhibitor of NOS, 
may have a key role in vascular regulation.
•  Compromised NO production may influence morbidity 
by disrupting microcirculatory blood flow and also could 
potentially compromise key bactericidal functions in the 
host.
•  Increased ADMA levels are associated with multiple 
organ failure and shock in the setting of a septic insult.
•  ADMA may be regulated by means of host genetic 
mechanisms, which influence the efficiency of the enzy-
matic breakdown of ADMA by DDAH II.Available online http://ccforum.com/content/10/5/R139
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